Elena Jansen1, Christina Hamisch2, Daniel Ruess3, Dieter Henrik Heiland4, Roland Goldbrunner2, Maximilian I Ruge3, Oliver Schnell4, Stefan J Grau5. 1. Department of Prosthetic Dentistry, University Hospital of Cologne, Kerpener Str. 62, 50937, Cologne, Germany. 2. Department of General Neurosurgery, Center for Neurosurgery, University Hospital Cologne, Kerpener Str. 62, 50937, Cologne, Germany. 3. Department of Stereotaxy and Functional Neurosurgery, Center for Neurosurgery, University Hospital Cologne, Kerpener Str. 62, 50937, Cologne, Germany. 4. Department of Neurosurgery, Medical Center University of Freiburg, Faculty of Medicine, University of Freiburg, Breisacher Str. 64, 79106, Freiburg, Germany. 5. Department of General Neurosurgery, Center for Neurosurgery, University Hospital Cologne, Kerpener Str. 62, 50937, Cologne, Germany. Stefan.grau@uk-koeln.de.
Abstract
PURPOSE: To provide detailed long-term data after initial observation for patients after histological confirmation of low grade (WHO II) gliomas according to molecular stratification. METHODS: A series of 110 patients with watchful waiting strategy after initial surgery for LGG and re-surgery at tumor progression were analyzed. Progression-free survival, time to malignant transformation, post-recurrence survival, and overall survival were estimated with the Kaplan-Meier method. Prognostic factors were identified by the Log Rank test and Cox multivariate proportional hazards model. RESULTS: The cohort comprised 18 IDH wild type (IDHwt) and 53 IDH mutated (IDHmut) astrocytomas, and 39 IDH mutated and 1p 19q co-deleted (IDHmut/codel) patients. The median follow-up was 126 (95% CI 109-143) months. Surgery was gross total resection in 58, subtotal resection in 28, and biopsy in 24 patients. Progression-free survival rates at 5, 10 and 15 years was 38% 18% and 1%. The corresponding malignant transformation rates were 17%, 39% and 71%. The initial extent of resection influenced progression-free survival, time to malignant transformation and overall survival. Molecular subtype IDHmut/codel was the strongest prognostic factor for overall survival and for time to malignant transformation. CONCLUSION: The strongest determinant of the patients' course after initial watchful waiting was the molecular tumor status. Extensive resection may increase time to progression and malignant transformation. Observation may be justified in selected patients.
PURPOSE: To provide detailed long-term data after initial observation for patients after histological confirmation of low grade (WHO II) gliomas according to molecular stratification. METHODS: A series of 110 patients with watchful waiting strategy after initial surgery for LGG and re-surgery at tumor progression were analyzed. Progression-free survival, time to malignant transformation, post-recurrence survival, and overall survival were estimated with the Kaplan-Meier method. Prognostic factors were identified by the Log Rank test and Cox multivariate proportional hazards model. RESULTS: The cohort comprised 18 IDH wild type (IDHwt) and 53 IDH mutated (IDHmut) astrocytomas, and 39 IDH mutated and 1p 19q co-deleted (IDHmut/codel) patients. The median follow-up was 126 (95% CI 109-143) months. Surgery was gross total resection in 58, subtotal resection in 28, and biopsy in 24 patients. Progression-free survival rates at 5, 10 and 15 years was 38% 18% and 1%. The corresponding malignant transformation rates were 17%, 39% and 71%. The initial extent of resection influenced progression-free survival, time to malignant transformation and overall survival. Molecular subtype IDHmut/codel was the strongest prognostic factor for overall survival and for time to malignant transformation. CONCLUSION: The strongest determinant of the patients' course after initial watchful waiting was the molecular tumor status. Extensive resection may increase time to progression and malignant transformation. Observation may be justified in selected patients.
Authors: Jan C Buckner; Edward G Shaw; Stephanie L Pugh; Arnab Chakravarti; Mark R Gilbert; Geoffrey R Barger; Stephen Coons; Peter Ricci; Dennis Bullard; Paul D Brown; Keith Stelzer; David Brachman; John H Suh; Christopher J Schultz; Jean-Paul Bahary; Barbara J Fisher; Harold Kim; Albert D Murtha; Erica H Bell; Minhee Won; Minesh P Mehta; Walter J Curran Journal: N Engl J Med Date: 2016-04-07 Impact factor: 91.245
Authors: Krzysztof Majchrzak; Wojciech Kaspera; Barbara Bobek-Billewicz; Anna Hebda; Gabriela Stasik-Pres; Henryk Majchrzak; Piotr Ładziński Journal: Clin Neurol Neurosurg Date: 2012-03-17 Impact factor: 1.876
Authors: Jan Coburger; Andreas Merkel; Moritz Scherer; Felix Schwartz; Florian Gessler; Constantin Roder; Andrej Pala; Ralph König; Lars Bullinger; Gabriele Nagel; Christine Jungk; Sotirios Bisdas; Arya Nabavi; Oliver Ganslandt; Volker Seifert; Marcos Tatagiba; Christian Senft; Maximilian Mehdorn; Andreas W Unterberg; Karl Rössler; Christian Rainer Wirtz Journal: Neurosurgery Date: 2016-06 Impact factor: 4.654
Authors: Andrew L Lin; Michael White; Michelle M Miller-Thomas; Robert S Fulton; Christina I Tsien; Keith M Rich; Robert E Schmidt; David D Tran; Sonika Dahiya Journal: J Neurooncol Date: 2016-10-04 Impact factor: 4.130
Authors: Ryan S Youland; Cole R Kreofsky; David A Schomas; Paul D Brown; Jan C Buckner; Nadia N Laack Journal: J Neurooncol Date: 2017-08-23 Impact factor: 4.130
Authors: M J van den Bent; D Afra; O de Witte; M Ben Hassel; S Schraub; K Hoang-Xuan; P-O Malmström; L Collette; M Piérart; R Mirimanoff; A B M F Karim Journal: Lancet Date: 2005 Sep 17-23 Impact factor: 79.321
Authors: Edward G Shaw; Brian Berkey; Stephen W Coons; Dennis Bullard; David Brachman; Jan C Buckner; Keith J Stelzer; Geoffrey R Barger; Paul D Brown; Mark R Gilbert; Minesh Mehta Journal: J Neurosurg Date: 2008-11 Impact factor: 5.115
Authors: Arthur Hosmann; Matthias Millesi; Lisa I Wadiura; Barbara Kiesel; Petra A Mercea; Mario Mischkulnig; Martin Borkovec; Julia Furtner; Thomas Roetzer; Stefan Wolfsberger; Joanna J Phillips; Anna S Berghoff; Shawn Hervey-Jumper; Mitchel S Berger; Georg Widhalm Journal: Cancers (Basel) Date: 2021-05-21 Impact factor: 6.575